Arctic Vision
Arctic Vision is a Shanghai-based private ophthalmic biopharmaceutical company developing breakthrough therapies for retinal disease, dry eye, and refractive conditions across Asia-Pacific, anchored by its SCS Microinjector platform and lead asset ARVN001 for uveitic macular edema.
- Company typePrivate
- Founded2019
- HeadquartersShanghai, China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arctic Vision does
Arctic Vision is a Shanghai-based, privately held ophthalmic biopharmaceutical company founded in 2019 that develops and commercializes innovative therapies for retinal disease, dry eye, and ocular neuroprotection across China and the broader Asia-Pacific region. Its pipeline is anchored by ARVN001 (XIPERE® in the United States, ARCATUS®/锋脉® in Asia-Pacific), a proprietary triamcinolone acetonide suspension formulated for suprachoroidal administration via the patented SCS Microinjector® platform licensed from Clearside Biomedical; ARVN001 is the first and only approved suprachoroidal therapy globally for uveitic macular edema, with approvals from the US FDA, Australian TGA, and Singapore HSA, plus a New Drug Application formally accepted by China's CDE in January 2025. The company's portfolio additionally includes the iTEAR®/沁淯® extra-nasal neurostimulation device for drug-free dry eye treatment (launched in China in May 2024), gene therapy candidates ARVN601 and ARVN901, and multiple preclinical-to-Phase-II assets covering glaucoma, myopia, and presbyopia.
The company operates a dual-engine model that combines in-licensed pharmaceutical development with consumer-oriented device technologies, and in February 2026 announced an agreement to acquire MDCO Technology's ophthalmic device business (premium IOL, phakic lens, and refractive platforms), which will establish wholly-owned subsidiaries in Shanghai for biopharmaceutical R&D, Hangzhou for device manufacturing, and California for design and global collaboration. Commercially, Arctic Vision employs an enterprise field-sales model executed through strategic partnerships and direct regional operations: Santen Pharmaceutical holds exclusive China commercialization rights for ARVN001 (excluding Taiwan, Hong Kong, and Macau), with up to US$85 million in upfront and milestone payments due to Arctic Vision, while the company retains direct commercialization capabilities across Greater China, South Korea, ASEAN countries, India, Australia, and New Zealand.
Arctic Vision generates revenue primarily through licensing and milestone payments rather than direct product sales, with revenue mechanics dominated by upfront fees, development and regulatory milestones, and commercial milestones from partners such as Santen and Clearside Biomedical. The company is backed by Nan Fung Life Sciences, Pivotal bioVenture Partners, Morningside Ventures, Loyal Valley Capital, Tencent Investment, Octagon Capital, and Dr. Adrian Cheng, having raised approximately US$132 million across two disclosed rounds (US$32M Series A in 2020, US$100M Series B in 2021). Leadership is drawn from senior ophthalmic roles at Allergan China, Alcon, Novartis Basel, MSD, and Boehringer Ingelheim, with Founder, Chairman and CEO Dr. Eddy Wu holding 14 patents and 23 academic publications.
Arctic Vision firmographics
Firmographics- Name
- Arctic Vision
- Legal name
- 极目峰睿（上海）生物科技有限公司
- Website
- https://arcticvision.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Arctic Vision is a Shanghai-based private ophthalmic biopharmaceutical company developing breakthrough therapies for retinal disease, dry eye, and refractive conditions across Asia-Pacific, anchored by its SCS Microinjector platform and lead asset ARVN001 for uveitic macular edema.
- Ownership category
- akta.pro rank
Arctic Vision industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industries
- Retina & Vitreous Specialists (HLAKAKAE), Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH), Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)
Keywords
Where Arctic Vision is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices7 records
Markets served
Arctic Vision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing and milestone payments: Arctic Vision generates revenue through licensing deals including upfront payments, development milestones, regulatory milestones, and commercial milestones. Example: Santen collaboration provides up to US$85 million in upfront and milestone payments for ARVN001 commercialization rights in China.
- Product sales (future): Future revenue from commercialization of pharmaceutical and device products in ophthalmology. Pipeline spans from pre-clinical to commercial stage products covering retinal disease, dry eye, and ocular neuroprotection.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Arctic Vision product offering
Product offeringCore offering
Arctic Vision is a China-based ophthalmic biotech that develops and commercializes breakthrough therapies for retinal diseases, dry eye, glaucoma, myopia, and presbyopia. Its core offerings include proprietary suprachoroidal space injectable therapy ARVN001 (ARCATUS®/XIPERE®/锋脉®) for uveitic macular edema and the iTEAR® (泪沁) tear neurostimulation device for dry eye, supported by a pipeline spanning preclinical to commercial stage programs combining novel drug delivery, gene therapy, and ophthalmic medical devices.
Differentiator
Problem solved
Functional benefit
Brands
- ARCATUS: Brand name for ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension) for treatment of uveitic macular edema. Known as XIPERE in the U.S.
- 锋脉
- iTEAR睦沁
Products and services
- ARVN001 (ARCATUS® / XIPERE® / 锋脉®) Proprietary suspension of corticosteroid triamcinolone acetonide formulated for suprachoroidal space administration, delivered via the patented SCS Microinjector®. Indicated for uveitic macular edema with demonstrated superior efficacy (38.5% of patients gained ≥15 ETDRS letters vs 9.4% control) and reduced adverse events versus traditional corticosteroid treatments. Marketed in the U.S. by Clearside Biomedical, in Australia as ARCATUS®, in China as 锋脉®, and via Santen Pharmaceutical as commercialization partner in mainland China.
- iTEAR® (泪沁) Tear Neurostimulation Device Non-invasive extra-nasal neurostimulation medical device that promotes natural tear production through specific vibration frequency stimulation. A drug-free, preservative-free, and natural treatment for adult patients with dry eye disease caused by insufficient tear secretion or poor tear quality. Awarded the Excellent Product Innovation Award at the Hong Kong Enterprise Innovation Project Selection 2024.
Quantifiable outcome
- 38.5% of ARVN001-treated patients achieved ≥15 ETDRS letter vision improvement vs 9.4% in sham group (p<0.001)
- +4 more outcomes
Companies that use Arctic Vision
Customer profileSegments4 records
Ideal customer profiles3 records
Arctic Vision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Arctic Vision partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- MDCO Technology (麦得科科技)coreArctic Vision agreed to acquire MDCO Technology's ophthalmic device business including premium intraocular lens, phakic lens, and refractive device platforms. MDCO becomes a wholly owned subsidiary with operations in Shanghai (biopharmaceutical R&D), Hangzhou (device manufacturing), and California (design and global collaboration). The transaction integrates MDCO's device engineering with Arctic Vision's pharmaceutical capabilities to form a comprehensive ophthalmic innovation ecosystem.
- Santen PharmaceuticalcoreCommercial collaboration agreement where Arctic Vision grants Santen exclusive commercialization rights for ARVN001 in China (excluding Taiwan, Hong Kong, Macau) for treatment of uveitic macular edema and other ophthalmic indications. Arctic Vision to receive up to US$85 million in upfront, milestone payments. Santen brings strong commercial capability with 130+ years of eye health expertise serving 50+ million people in 60+ countries.
- Clearside BiomedicalcoreLicensed XIPERE® (ARVN001) for suprachoroidal space injection therapy. Clearside's patented SCS Microinjector® technology enables drug delivery to suprachoroidal space. Arctic Vision obtained exclusive rights for Greater China and South Korea (March 2020), ASEAN and India (August 2021), Australia and New Zealand (September 2021).
- Bausch + LombminorListed as a partner company, providing contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded 1853 with 12,000+ employees in nearly 100 countries.
- ActualEyesminorJapanese clinical stage biotech company developing cell therapy and pharmacological treatments for corneal endothelial dysfunction including Fuchs endothelial corneal dystrophy (FECD) and bullous keratopathy. Founded based on research from Doshisha University, Kyoto.
- Olympic OphthalmicsminorMedical technology company pioneering patient-focused treatments for ophthalmic diseases using neuromodulation. Based in Issaquah, Washington, backed by BioStar Capital.
- University of Hong Kong - LKS Faculty of MedicineminorResearch partnership with Department of Ophthalmology conducting multi-center clinical treatment trials for retinal macular diseases, developing ocular gene therapy for glaucoma, and innovating treatment paradigms for cataract surgery outcomes.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Arctic Vision competitors and assessment
Company assessmentDirect peers
- Clearside Biomedical: Clearside Biomedical (NASDAQ: CLSD) is the originator of the SCS Microinjector suprachoroidal drug delivery platform and developed XIPERE (ARVN001) — the same asset Arctic Vision has licensed for Asia-Pacific, making it the most directly comparable peer in suprachoroidal delivery and ophthalmic drug development.
- EyePoint Pharmaceuticals: EyePoint Pharmaceuticals (NASDAQ: EYPT) is a clinical-stage biopharma developing sustained-release ocular drug delivery (DURASERT for retinal diseases including UME), directly comparable to Arctic Vision's suprachoroidal and specialty ophthalmic drug pipeline targeting similar indications.
- Ocular Therapeutix: Ocular Therapeutix (NASDAQ: OCUL) is a clinical-stage biopharma developing sustained-release intracanalicular and intravitreal ophthalmic therapies (e.g., DEXTENZA, OTX-TKI), paralleling Arctic Vision's focus on novel ophthalmic drug delivery for retinal and anterior segment diseases.
- Eyenovia: Eyenovia (NASDAQ: EYEN) is a clinical-stage ophthalmic biopharma developing microdose array print (MAP) delivery for presbyopia, myopia progression, and mydriasis; an existing Arctic Vision partner and directly comparable in novel ophthalmic drug/device delivery technology.
- Olympic Ophthalmics: Olympic Ophthalmics is a US neuromodulation-focused medical technology company pioneering patient-focused treatments for ophthalmic diseases; directly comparable to Arctic Vision's iTEAR extra-nasal neurostimulation device for dry eye disease.
Broad incumbents
- Santen Pharmaceutical: Santen is a 130+ year Japan-headquartered global ophthalmic specialty pharmaceutical company operating in 60+ countries; it is both Arctic Vision's exclusive China commercialization partner for ARVN001 and a direct competitor in retinal, glaucoma, and dry eye therapeutics across Asia-Pacific.
- Alcon: Alcon is a global ophthalmic medical device and pharmaceutical leader (surgical, vision care, dry eye); Arctic Vision's leadership team includes multiple Alcon alumni and the two compete across retina, glaucoma, dry eye, and surgical device categories in Asia.
- Bausch + Lomb: Bausch + Lomb is a global ophthalmic pharmaceutical, surgical, and vision care company (12,000+ employees, 100+ countries) and an existing Arctic Vision partner; overlaps across ophthalmic pharma, contact lenses, and surgical devices with Arctic Vision's drug-device platform.
Regional players
- Zhaoke Ophthalmology (China): Zhaoke Ophthalmology is a China-based ophthalmic pharma company developing innovative therapies for retinal and other eye diseases (listed on HKEX); operates in the same Asia-Pacific ophthalmology specialty pharma category as Arctic Vision but with a China-domestic focus.
- Eyebright Medical Technology: Eyebright Medical is a leading China-based ophthalmic medical device company specializing in intraocular lenses and ophthalmic surgical products; directly comparable to Arctic Vision's MDCO Technology subsidiary following the 2026 acquisition of premium IOL and refractive device platforms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Arctic Vision social profiles
Digital presenceArctic Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arctic Vision leadership team
Management profileNumber of profiles
Profiles4 records
Arctic Vision subsidiaries and ownership
Company hierarchySubsidiaries2 records
Arctic Vision funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arctic Vision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arctic Vision
What does Arctic Vision do?
Arctic Vision is a China-based ophthalmic biotech that develops and commercializes breakthrough therapies for retinal diseases, dry eye, glaucoma, myopia, and presbyopia. Its core offerings include proprietary suprachoroidal space injectable therapy ARVN001 (ARCATUS®/XIPERE®/锋脉®) for uveitic macular edema and the iTEAR® (泪沁) tear neurostimulation device for dry eye, supported by a pipeline spanning preclinical to commercial stage programs combining novel drug delivery, gene therapy, and ophthalmic medical devices.
Is Arctic Vision a public or private company?
Arctic Vision is a private company. It is classified as venture growth investor backed and is currently operating.
When was Arctic Vision founded?
Arctic Vision was founded in 2019. It employs 101 to 250 people.
Where is Arctic Vision based?
Arctic Vision is headquartered in Shanghai, China, in the Asia region.
How does Arctic Vision make money?
Two revenue lines are on record. Licensing and milestone payments are the primary driver. The others are product sales (future).
Who are Arctic Vision's main competitors?
Direct peers on record are Clearside Biomedical, EyePoint Pharmaceuticals, Ocular Therapeutix, Eyenovia and Olympic Ophthalmics. Broad incumbents are Santen Pharmaceutical, Alcon and Bausch + Lomb. Regional players are Zhaoke Ophthalmology (China) and Eyebright Medical Technology.
Does Arctic Vision have an API?
No public API is recorded for Arctic Vision.
What industry is Arctic Vision in?
Arctic Vision's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 339115 and its SIC code is 3841.